Search
for
Sort by
Research 541–570 of 575
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Baricitinib Induced Hypoglycemic Seizures in a Patient with Hair Loss and Type I Diabetes Mellitus: A Case Report
- Anticancer Effects of Cepharanthine: an Updated Minireview
- Effects of the RV3466F lotion on female telogen effluvium: Results from a 16 week, multi-centric, controlled, randomized trial
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
- Hair for the Long Haul: Alopecia Areata Cases and Considerations
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
- “<i>Nomen Omen</i>: The Myth of God Janus”
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection
- Pathologic Quiz Case: An Anterior Neck Mass in a 5-Month-Old Female Infant
- Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
- Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study
- Delayed granulomatous eruption of the nose associated with ruxolitinib
- Antioxidant and 5α-Reductase Inhibitory Activity of Momordica charantia Extract, and Development and Characterization of Microemulsion
- Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways